BNET Industries
Genzyme Corp. (GENZ) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $3.8B
- Profit
- Dec 31 2007
- $480.1M
- Market Cap
- Jul 22 2008
- $12.5M
Latest News and Analysis
Genzyme Corp. Q2 2008 Earnings Call Transcript
Genzyme Corp. GENZ Q2 2008 Earnings Call
PTC and Genzyme in $437M Gene Therapy Deal
Eben Tessari submits:Image via Wikipedia Talk about a good week for PTC. A day after announcing the Cystic Fibrosis Foundation is dropping $25M on PTC124 (PTC’s novel oral therapy in late-stage development for the treatment of genetic disorders due to nonsense mutations) and funding the phase 2 trial,...
Big Biotech Booms But IBB Falls Flat
Don Dion submits: Shares in the biotech firm Amgen AMGN shot up Monday morning after the firm announced major developments for two of its products: Nplate, a drug designed to treat a rare form of blood-platelet deficiency, received final approval from the FDA, and the results of a...
In Tech We Trust - Fast Money Recap (6/20/08)
Recap of Fast Money, Friday June 20. Dow Falls Below 12,000 by SA Editor Joan Wickham
FDA Stings Pharma, Big and Small
Michael Steinberg submits: The first shock came after Merck MRK and Schering-Plough’s SGP Vytorin ENHANCE study. Surrogate markers like cholesterol counts would no longer be enough to garner marketing approval. Genzyme GENZ and Isis ISIS received the first blow. Isis’ cholesterol drug Mipomersen would have to undergo an outcomes study...
Biotech Fundamentals Still Look Strong
A. Reza Saadat submits: Back in January, I wrote an article predicting a good year for the Biotechnology/Biopharma sector based on early performance vs. major indices. Here is a link to that article.Five months have passed since that post was published and I have written very few articles since....
Genzyme Corp. Q1 2008 Earnings Call Transcript
Genzyme Corp. Q1 2008 Earnings Call Transcript
Why Biogenerics Will Survive Genzyme's Problems
The Food and Drug Administration rejected Genzyme's request to sell a version of its drug Myozyme made in a new factory, a decision some journalists and bloggers insist on casting as a black mark against the very notion of generic biotech drugs. There's just one problem: These...
Genzyme Corp. Q4 2007 Earnings Call Transcript
Genzyme Corp. Q4 2007 Earnings Call Transcript
Genzyme Q3 2007 Earnings Call Transcript
Genzyme Q3 2007 Earnings Call Transcript
Genzyme Q2 2007 Earnings Call Transcript
Genzyme Q2 2007 Earnings Call Transcript
Genzyme Q2 2007 Earnings Call Transcript
Genzyme Q2 2007 Earnings Call Transcript
Genzyme Q1 2007 Earnings Call Transcript
Genzyme Q1 2007 Earnings Call Transcript
Genzyme Q4 2006 Earnings Call Transcript
Genzyme Q4 2006 Earnings Call Transcript
Genzyme Q3 2006 Earnings Call Transcript
Genzyme Q3 2006 Earnings Call Transcript
Genzyme Corporation Q2 2006 Earnings Conference Call Transcript (GENZ)
Genzyme Corporation Q2 2006 Earnings Conference Call Transcript GENZ
Genzyme, Inc. Q1 2006 Earnings Conference Call Transcript (GENZ)
Genzyme, Inc. Q1 2006 Earnings Conference Call Transcript GENZ
Genzyme Q4 2005 Earnings Conference Call Transcript (GENZ)
Genzyme Q4 2005 Earnings Conference Call Transcript GENZ
Additional Resources
BullMarket.com Offers Investment Opinion on Biotech Stocks
PRINCETON, N.J. -- BullMarket.com (http://www.bullmarket.com), an online investment newsletter focused on long-term growth and income-generating stocks, announced today that it has provided subscribers with reports on biotech stocks, including Celgene(Nasdaq: CELG), Genzyme(Nasdaq: GENZ), Gilead Sciences(Nasdaq: GILD), and Amgen(Nasdaq: AMGN), among others. All paid and trial subscribers to BullMarket.com...
Research and Markets: Benchmark Genzymes Performance Against Key Rivals in the Ethical Pharmaceutical Sector Today
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/2b4f88/genzyme_corporatio) has announced the addition of the "Genzyme Corporation: Pharmavitae Profile" report to their offering. Introduction This analysis examines the historical and forecast performance for Genzyme in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline...
- Next »
- page 1 of 63
- « Previous
Sort byClose
- Incorporated: 1981
- CEO: Mr. Henri A. Termeer
Genzyme is a biotechnology company operating in five segments: Renal, which develops, produces and distributes products for patients with renal diseases; Therapeutics, which develops, produces and distributes therapeutic products such as products for treating genetic and other chronic debilitating diseases; Transplant, which develops, producess and distributes therapeutic products for pre-transplantation, prevention and treatment of acute rejection in organ transplantation, and other autoimmune disorders; Biosurgery, which develops, produces and distributes biotherapeutics and biomaterial products; and Genetics, which provides testing services for oncology, prenatal and reproductive markets.
Key Competitors
Genzyme Corp. Company Info
Board of Directors
Mr. Henri A. Termeer
Chairman
Mr. Douglas A. Berthiaume
Ms. Gail Koziara Boudreaux
Mr. Robert J. Carpenter
Dr. Charles L. Cooney Ph.D.
Mr. Richard F. Syron
Dr. Victor J. Dzau M.D.
Senator Cornelius McGillicudy III
Contact Information
500 Kendall Street
Cambridge, MA
617 252-7500
